Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage…
| Price | $56.15 |
|---|---|
| Market cap | $1.54B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| 52-week range | 14.27-66.37 |
| Beta | 0.9 |
Explore ETON's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.